Morgan Stanley strategists highlighted companies that look likely to impress with earnings including Chewy, Eaton, Nvidia, ...

Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

The move reveals both the power of philanthropic groups to sway legislators and a split in the administration’s coalition.

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Eli Lilly's revenue and earnings have been growing significantly faster than those of its similarly sized peers. That should continue for at least the next few years.

S&P 500, Microsoft Corporation, Eli Lilly and Company, Alphabet Inc Class A. Read 's Market Analysis on Investing.com ...

Demand for Eli Lilly’s LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving ...

Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per share in Q1 2025, missing analysts’ consensus estimate of $4.64. Despite this, ...